Antibody frequency for Toxoplasma gondii and Neospora spp. in domiciliated and stray cats from Araguaína, Tocantins, Eastern Amazonia

Toxoplasma gondii and Neospora spp. are protozoa that have a significant impact on animal health due to the diseases they cause in domestic and wild animals. The aim of the present study was to investigate the presence of antibodies against T. gondii and Neospora spp. in cats from northern Brazil. Serum samples were collected from 180 cats in the municipality of Araguaína, Tocantins and used to evaluate the presence of anti-T. gondii and anti-Neospora spp. antibodies using the indirect fluorescent antibody test, with a cutoff of 1:64 and 1:25, respectively. The association between infection and individual animal characteristics (age, sex, origin, breed, and clinical signs) was tested using univariate analysis, followed by multivariate logistic regression. We found that 48.3% (87/180) of the animals had anti-T. gondii (95% CI: 40.8%–55.90%) and 3.9% (7/180) had anti-Neospora spp. (95% CI: 1.6%–7.8%) antibodies. There was no association between age, sex, breed origin, clinical signs, and seropositivity for T. gondii. Cats of defined breeds were more likely to be infected by Neospora spp. (OR = 10.7). Therefore, we found a high rate of seropositivity for T. gondii and a high rate of occurrence of Neospora infections in cats from the Araguaína region. The exposure of the feline population to the studied coccidia indicates the need to monitor the feline population for these infections and underscores the importance of effective sanitary measures against such pathogens.

Determination of Sero-Prevalence of SARS-CoV-2 antibody among immunized individuals with Covid-19 vaccine in a tertiary center, Nepal

Background: Coronavirus Disease 2019 (covid-19) is a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). People who are infected with SARS-CoV-2 or are vaccinated with covid-19 vaccines are supposed to develop immunoglobulins and these immune responses in human body will determine the efficacy of the vaccines as well as help to discover new therapeutic options. Methods: A cross-sectional study conducted between April to June, 2021, assessing serum antibody titer from participants who had taken the first dose of covishieldTM vaccine (naïve as well as prior covid-19 infected individuals). Antibody testing was carried out with Roche Elecsys Anti-SARS-CoV-2 S electrochemiluminescence immunoassay on Roche Cobas e 601 module. Twenty-eight of these participants had follow up repeat antibody test after second dose of vaccine. Results: A total of 122 participants with the first dose of CovishieldTM vaccine were all tested seropositive, antibody titer ranging from minimum of 2.95 U/mL to maximum 2500 U/mL. Average antibody titer was 308.9 U/mL for naive cohort and 1604 U/mL for prior covid-19 infection. In twenty-eight participants who had antibody titer measured after 1 month of second dose, average titer was 1459.7 U/mL for naïve cohort and 1803.4 U/mL for prior covid-19 infected individuals, which was statistically significant compared to antibody response after the first dose. Conclusions: Antibody responses against SARS-CoV-2 following immunization was 100%, with significant development after second dose in naïve population while robust immune response was present after first dose in prior SARS-CoV-2 infected individuals.

Use of a Direct, Rapid Immunohistochemical Test for Diagnosis of Rabies Virus in Bats

Rabies, a zoonotic encephalitis due to transmission of a lyssavirus, such as rabies virus (RABV), has the highest case fatality of any infectious disease. A global program for the elimination of human rabies caused by dogs is proposed for realization by 2030. Sensitive, specific, and inexpensive diagnostic tests are necessary for enhanced surveillance to detect infection, inform public health and veterinary professionals during risk assessments of exposure, and support overall programmatic goals. Multiple laboratory techniques are used to confirm a suspect case of rabies. One method for the detection of lyssavirus antigens within the brain is the direct rapid immunohistochemical test (dRIT), using light microscopy, and suitable for use under field conditions. Besides dogs, other major RABV reservoirs reside among mammalian mesocarnivores and bats. To date, use of the dRIT has been applied primarily for the diagnosis of RABV in suspect mesocarnivores. The purpose of this study was to assess the usefulness of the dRIT to the diagnosis of rabies in bats, compared to the gold-standard, the direct fluorescent antibody test (DFAT). Brains of 264 suspect bats, consisting of 21 species from Arizona and Texas, were used in the evaluation of the dRIT. The overall sensitivity of the dRIT was 100% (0.969–1.0, 95% CI) and the specificity was 94.6% (0.896–0.976, 95% CI), comparable to the DFAT. This preliminary study demonstrated the utility of the dRIT in the confirmation of RABV infection in bats. Future studies should include additional geographic, lyssavirus, and mammalian species representations for broader application during enhanced rabies surveillance, with incorporation of any potential adjustments to standard protocols, as needed.

The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody

To satisfy the microbiologic criteria of the current diagnostic guideline for nontuberculous mycobacterial pulmonary disease (PD), at least two positive sputum cultures of the same species of mycobacteria from sputum are required to avoid the casual isolation of mycobacteria. This study showed that the positivity of a serum anti-glycopeptidolipid (GPL)-core IgA antibody test has an excellent diagnostic ability among patients with radiologically suspected Mycobacterium avium complex (MAC)-PD or Mycobacterium abscessus (MAB)-PD who already had a single positive sputum culture test.

A Crossectional Study of Rajayakshma Symptoms in HIV Positive Patients

Background: According to Ayurveda, the HIV Symptoms may be correlated with Rajayakshama (Kshaya). The Symptoms, causative factors and treatment for the latter were found mentioned in many ancient Ayurvedic texts. Present study was aimed to assess the correlation of Rajayakshama symptoms described in Charak Samhita and symptoms seen in HIV positive patient. Material and Method: Present study was a Cross-sectional Survey Study, conducted in patientsof 25 - 50 years age group, irrespective of sex, religion, economic & marital status, diagnosed patients of HIV antibody test positive minimum 2 year ago.Results: Maximum number of HIV patient were from 31-40 years age group(67%). Majority of HIV patients were Female (81%).53 % patients’ were HIV Antibody Test Positive more than 2 year ago & 47% patients were more than 10 year ago.97 % patients were on ART Medication and only 3% patients were not given ART Medication.Ansatapa, Jwara and Parshwashulawere observed in all 100% patient. other symptoms Shirashula(99%); Aruchi(96%);Swarabheda(94%); Swasa(87%); Kasa(60%), Atisara(51 %); Raktasthivana(12%) and Raktavamana(4%). 69% cases were observed with 8-11 symptoms of Rajayakshma. 30% cases had 5-7 symptoms and only 1% cases had 1-4 symptoms of Rajayakshma.Conclusion: this disease is more related to mental status of the person. Following Dinacharya, Rutucharya, Sadvrittapalana, Aachararasayana etc. explained in Ayurveda will definitely help in treating AIDS and improving patient’s health.

Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples

COVID-19 has affected billions of people around the world directly or indirectly. The response to the pandemic has focused on preventing the spread of the disease and improving treatment options. Diagnostic technologies have played a key role in this response since the beginning of the pandemic. As vaccines and other treatments have been developed and deployed, interest in understanding and measuring the individual level of immune protection has increased. Historically, use of antibody titers to measure systemic immunity has been constrained by an incomplete understanding of the relationship between antibodies and immunity, the lack of international standards for antibody concentration to enable cross-study comparisons, and insufficient clinical data to allow for the development of robust antibody-immunity models. However, these constraints have recently shifted. With a deeper understanding of antibodies, the promulgation of WHO antibody standards, and the development of immunity models using datasets from multiple COVID-19 vaccine trials, certain types of quantitative antibody tests may now provide a way to monitor individual or community immunity against COVID-19. Specifically, tests that quantitate the concentration of anti-RBD IgG -antibodies that target the receptor binding domain of the S1 spike protein component of the SARS-CoV-2 virus- show promise as a useful and scalable measure of the COVID-19 immunity of both individuals and communities. However, to fulfill this promise, a rapid and easy-to-administer test is needed. To address this important clinical need, Brevitest deployed its point-of-care-capable technology platform that can run a rapid (<15 minute), quantitative antibody test with a sample of 10 µl of whole blood from a fingerstick. The test we validated on this platform measures the concentration of anti-RBD IgG in Binding Antibody Units per milliliter (BAU/mL) per WHO Reference Standard NIBSC 20/136. In this paper, we present studies used to characterize the Brevitest anti-RBD IgG assay and evaluate its clinical performance, lower limits of measurement, precision, linearity, interference, and cross-reactivity. The results demonstrate the ability of this assay to measure a patient's anti-RBD IgG concentration. This information, together with models developed from recent COVID-19 vaccine clinical trials, can provide a means of assessing the current level of immune protection of an individual or community against COVID-19 infection.

Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy

Background and ObjectivesTo describe the clinical features of anti-NMDAR encephalitis, emphasizing on late-onset patients and antibody test characteristics in serum and CSF.MethodsNationwide observational Dutch cohort study, in patients diagnosed with anti-NMDAR encephalitis between 2007 and 2019.ResultsOne hundred twenty-six patients with anti-NMDAR encephalitis were included with a median age of 24 years (range 1–86 years). The mean annual incidence was 1.00/million (95% CI 0.62–1.59). Patients ≥45 years of age at onset (19%) had fewer seizures (46% vs 71%, p = 0.021), fewer symptoms during disease course (3 vs 6 symptoms, p = 0.020), and more often undetectable serum antibodies compared with younger patients (p = 0.031). In the late-onset group, outcome was worse, and all tumors were carcinomas (both p < 0.0001). CSF was more accurate than serum to detect anti-NMDAR encephalitis (sensitivity 99% vs 68%, p < 0.0001). Using cell-based assay (CBA), CSF provided an unconfirmed positive test result in 11/2,600 patients (0.4%); 6/11 had a neuroinflammatory disease (other than anti-NMDAR encephalitis). Patients with anti-NMDAR encephalitis, who tested positive in CSF only, had lower CSF antibody titers (p = 0.003), but appeared to have an equally severe disease course.DiscussionAnti-NMDAR encephalitis occurs at all ages and is less rare in the elderly patients than initially anticipated. In older patients, the clinical phenotype is less outspoken, has different tumor association, and a less favorable recovery. Detection of antibodies in CSF is the gold standard, and although the CBA has very good validity, it is not perfect. The clinical phenotype should be leading, and confirmation in a research laboratory is recommended, when in doubt.